Alnylam Pharmaceuticals (ALNY) Non Operating Investment Income (2014 - 2017)

Alnylam Pharmaceuticals (ALNY) has 3 years of Non Operating Investment Income data on file, last reported at -$345000.0 in Q2 2017.

• Quarterly Non Operating Investment Income fell 136.16% year-over-year to -$345000.0 in Q2 2017, while the trailing twelve-month figure through Dec 2017 was -$1.9 million (down 127.15% YoY) and the FY2017 annual result came in at -$1.9 million, down 127.15% from the prior year.
• Non Operating Investment Income improved to -$345000.0 in Q2 2017, from -$1.5 million in the prior quarter.
• In the past five years, Non Operating Investment Income ranged from a high of $5.2 million in Q1 2016 to a low of -$1.5 million in Q1 2017.
• A 3-year average of $895500.0 and a median of $636500.0 in 2014 frame the typical range for Non Operating Investment Income.
• The widest YoY moves for Non Operating Investment Income: up 130.04% in 2017, down 136.16% in 2017.
• Tracing ALNY's Non Operating Investment Income over 3 years: stood at $1.5 million in 2014, then tumbled by 89.37% to $161000.0 in 2016, then sank by 314.29% to -$345000.0 in 2017.
• The last three Non Operating Investment Income figures came in at -$345000.0 (Q2 2017), -$1.5 million (Q1 2017), and $161000.0 (Q4 2016), per Business Quant data.